John M. Aoki
Plus aucun poste en cours
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Stephen Moore | M | 59 | 10 ans | |
Salvatore Salibello | M | 78 | 4 ans | |
David L. Clark | M | 70 |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 19 ans |
Marc Gabelli | M | 56 | 7 ans | |
Kimberly V. Rogers | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 20 ans |
Chad Bello | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 22 ans |
Robert R. Becklin | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 22 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Gregg Engles | M | 65 | 18 ans | |
Gregg A. Tanner | M | 67 | 10 ans | |
Rachel Gonzalez | F | 54 | 6 ans | |
Gary Sugarman | M | 71 | 15 ans | |
Michelle Goolsby | F | 66 | 10 ans | |
Scott Vopni | M | 55 | 11 ans | |
Daniel E. Hopkins | M | - | 1 ans | |
J. Wayne Mailloux | M | 75 | 11 ans | |
Kent Misener | M | 72 |
Utah State University
| 6 ans |
Brian Clement Israelsen | M | - |
Utah State University
| 5 ans |
V. Kelly Randall | M | 73 |
Utah State University
| 6 ans |
C. Shay Braun | M | 56 | 9 ans | |
Kimberly Warmbier | F | 62 | 5 ans | |
Donald Hunter | M | 67 | 1 ans | |
Joseph Scalzo | M | 65 | 6 ans | |
Shaun Mara | M | 60 | 3 ans | |
Hui Tang | F | 64 |
Utah State University
| 6 ans |
Doreen A. Wright | F | 67 | 4 ans | |
Sherri Baker | F | 51 | 2 ans | |
Liliana Esposito | F | 49 | 4 ans | |
Rick Collins | M | - |
Utah State University
| 6 ans |
Jay Dee Clayton | M | 71 |
Utah State University
| 4 ans |
Gar Forman | M | - |
Utah State University
| 4 ans |
Kent R. van Kampen | M | - |
Utah State University
| 4 ans |
Robert Irvin | M | - |
Utah State University
| 4 ans |
Timothy Burns | M | 49 | 9 ans | |
Thomas N. Zanetich | M | 72 | - | |
Kelly Duffin-Maxwell | F | 59 | - | |
Matthew Favre | M | - | - | |
Gregory McKelvey | M | 51 | 7 ans | |
Rick L. Johnson | M | 70 |
Utah State University
| 4 ans |
Abdul Hapiz bin Abdullah | M | 66 |
Utah State University
| 3 ans |
Sanah Marah | M | 46 | 4 ans | |
Jose A. Motta | M | 59 | 7 ans | |
Michael Nathenson | M | 60 | 3 ans | |
Carrie Tharp | F | 43 | 3 ans | |
Wesley D. Bigler | M | - |
Utah State University
| 4 ans |
Don A. Tanner | M | - |
Utah State University
| 4 ans |
Daren Shaw | M | 67 |
Utah State University
| 4 ans |
Edward F. Fugger | M | 56 | 8 ans | |
Rachel P. Cullen | F | 65 | 5 ans | |
Andy Smith | M | - |
Utah State University
| 7 ans |
Trisha L. Fox | F | 54 | 2 ans | |
Jerrold N. Mayer | M | - |
Utah State University
| 1 ans |
Steven McDowell | M | 62 | 6 ans | |
Brian Murphy | M | 56 | - | |
Richard Gillis | M | - | - | |
Richard Zuroweste | M | - | - | |
James F. Kohler | M | 76 |
Utah State University
| 1 ans |
Joseph H. Gardner | M | 68 |
Utah State University
| 1 ans |
John Callahan | M | 66 | 4 ans | |
Ronald Kirk | M | 69 | 6 ans | |
Melinda Scissors Conley | F | 58 | 5 ans | |
Rory Lee Miller | M | 63 |
Utah State University
| 4 ans |
Christopher D. Sliva | M | 60 | 6 ans | |
Gary M. Julien | M | 54 | - | |
Paul T. Moskowitz | M | 60 | 4 ans | |
Ronald L. McCrummen | M | 59 | 6 ans | |
Pete Schenkel | M | 88 | 9 ans | |
Ronald H. Klein | M | 58 | 7 ans | |
Elliott N. Taylor | M | 65 |
Utah State University
| 4 ans |
Kenneth C. Johnsen | M | 65 |
Utah State University
| 4 ans |
E. Heiner | M | 62 |
Utah State University
| 6 ans |
John S. Llewellyn | M | 89 | 6 ans | |
Lewis Collens | M | 88 | 8 ans | |
Alan J. Bernon | M | - | 11 ans | |
Jonathon Bunker | M | 64 |
Utah State University
| 4 ans |
Gary E. Stevenson | M | 68 |
Utah State University
| 4 ans |
Bryce M. Petersen | M | - |
Utah State University
| 4 ans |
Deborah B. Carosella | F | 67 | - | |
Alan K. Smith | M | 68 |
Utah State University
| 7 ans |
Harrald F. K. Kroeker | M | 66 | 4 ans | |
William A. Swanston | M | 70 | 3 ans | |
Bradly A. Oldroyd | M | - |
Utah State University
| 4 ans |
Robert K. Reynolds | M | - |
Utah State University
| 4 ans |
Christopher Bellairs | M | 63 | 9 ans | |
Leland George Foster | M | 78 |
Utah State University
| 4 ans |
Thomas D. Ingolia | M | 71 |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | - |
Eric Harrison Edwards | M | 68 |
Utah State University
| 4 ans |
James DaBramo | M | 65 | 6 ans | |
Prasert Bunsumpun | M | 72 |
Utah State University
| 2 ans |
Scott R. Watterson | M | 68 |
Utah State University
| 4 ans |
Barbara D. Carlini | F | 63 | 4 ans | |
Avrum Gray | M | 88 | - | |
Andrew Judd | M | - | 2 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 92 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- John M. Aoki
- Réseau Personnel